Lonza published a research paper on mammalian genes combining to make previously uncharacterized proteins.
Published
Signal category
Research & Knowledge
Quote
“mammalian-genes-can-combine-to-make-previously-activity”
— Bingnan Gu, PhD, MBA|Lonza team
Company
Lonza
Making the Medicines of Tomorrow
- Industry
- Pharmaceutical Manufacturing
- Location
- Basel, CH
- Company size
- 19,351 employees
Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.
Founded 1897